1. Home
  2. LXEO

as 05-30-2025 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Nasdaq

Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.

Founded: 2017 Country:
United States
United States
Employees: N/A City: NEW YORK
Market Cap: 93.9M IPO Year: 2023
Target Price: $18.50 AVG Volume (30 days): 984.8K
Analyst Decision: Strong Buy Number of Analysts: 6
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -3.31 EPS Growth: N/A
52 Week Low/High: $1.45 - $19.50 Next Earning Date: 05-12-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

LXEO Daily Stock ML Predictions

Share on Social Networks: